Related Experiment Video

Updated: May 2, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

The heart-liver metabolic axis: defective communication exacerbates disease

Kedryn K Baskin1, Angie L Bookout, Eric N Olson

  • 1Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

EMBO Molecular Medicine
|March 14, 2014
PubMed

Insights

A genetic heart defect disrupts communication between the heart and liver, worsening hypertrophic cardiomyopathy (HCM) by altering liver lipid metabolism. This study reveals critical heart-liver crosstalk in disease.

Area of Science:

  • Cardiovascular Endocrinology
  • Metabolic Disease
  • Organ Crosstalk

Background:

  • The heart is recognized as an endocrine organ, but its communication with other organs, especially in disease, remains poorly understood.
  • Hypertrophic cardiomyopathy (HCM) is a cardiac condition where understanding inter-organ communication is crucial for disease progression.

Purpose of the Study:

  • To investigate the communication pathways between the heart and liver.
  • To explore how a primary cardiac genetic defect impacts hepatic lipid metabolism and exacerbates hypertrophic cardiomyopathy (HCM).
  • To test the hypothesis of disrupted heart-liver crosstalk in diseased states.

Main Methods:

  • The study introduces a conceptual framework linking cardiac genetic defects to hepatic lipid metabolism.
  • Evidence is presented to support the proposed heart-liver communication axis.
  • Focus on the consequences of aberrant hepatic lipid metabolism in the context of HCM.

Main Results:

  • A primary genetic defect in the heart leads to abnormal lipid metabolism in the liver.
  • This aberrant hepatic lipid metabolism was shown to worsen the severity of hypertrophic cardiomyopathy (HCM).
  • The findings support the existence of crosstalk between the heart and liver.

Conclusions:

  • Heart-liver crosstalk is a significant factor in cardiovascular health.
  • Disruption of this communication pathway, particularly altered hepatic lipid metabolism, exacerbates cardiac disease like HCM.
  • Understanding this inter-organ communication offers potential therapeutic targets for managing hypertrophic cardiomyopathy.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
358
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379